AICAR vs Mirabegron (YM-178)

Human trials used supervised IV infusion (acadesine, up to 210 mg/kg in the CLL study); there is no validated oral or subcutaneous human dose of the kind vendors market, and rodent efficacy used ~500 mg/kg/day subcutaneously. Small molecule (not a peptide); not FDA-approved.

FDA-approved dosing for overactive bladder is 25 mg once daily, increased to 50 mg after 4–8 weeks as a labeled pharmaceutical fact. Investigational metabolic research used 100 mg/day (double the approved maximum) to elicit brown adipose tissue activation—this is an off-label, non-approved dose studied only in controlled academic trials. Oral bioavailability is dose-dependent (~29% at 25 mg, ~35% at 50 mg); Tmax ~3.5 hours, elimination half-life ~50 hours. Unregulated 'research use only' powder sold by reagent vendors lacks pharmaceutical-grade quality control, sterility, or purity assurance.